46 related articles for article (PubMed ID: 11983265)
21. Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes.
van Baalen CA; Guillon C; van Baalen M; Verschuren EJ; Boers PH; Osterhaus AD; Gruters RA
Eur J Immunol; 2002 Sep; 32(9):2644-52. PubMed ID: 12207349
[TBL] [Abstract][Full Text] [Related]
22. The advantage of early recognition of HIV-infected cells by cytotoxic T-lymphocytes.
Gruters RA; van Baalen CA; Osterhaus AD
Vaccine; 2002 May; 20(15):2011-5. PubMed ID: 11983265
[TBL] [Abstract][Full Text] [Related]
23. CTL ontogeny and viral escape: implications for HIV-1 vaccine design.
Yang OO
Trends Immunol; 2004 Mar; 25(3):138-42. PubMed ID: 15036041
[No Abstract] [Full Text] [Related]
24. HIV T cell vaccines, the importance of clades.
McMichael A; Mwau M; Hanke T
Vaccine; 2002 May; 20(15):1918-21. PubMed ID: 11983245
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic T-cell epitopes in HIV/SIV infection.
Venet A; Walker BD
AIDS; 1993; 7 Suppl 1():S117-26. PubMed ID: 7689848
[No Abstract] [Full Text] [Related]
26. HIV-1 Tat vaccines.
Ensoli B; Cafaro A
Virus Res; 2002 Jan; 82(1-2):91-101. PubMed ID: 11885958
[No Abstract] [Full Text] [Related]
27. Tat and Rev: positive modulators of human immunodeficiency virus gene expression.
Rosen CA
Gene Expr; 1991 May; 1(2):85-90. PubMed ID: 1820213
[No Abstract] [Full Text] [Related]
28. Compatibility of Tat and Rev transactivators in the primate lentiviruses.
Sakai H; Sakuragi J; Sakuragi S; Kawamura M; Adachi A
Arch Virol; 1993; 129(1-4):1-10. PubMed ID: 8385908
[TBL] [Abstract][Full Text] [Related]
29. Alloimmunization for immune-based therapy and vaccine design against HIV/AIDS.
Shearer GM; Pinto LA; Clerici M
Immunol Today; 1999 Feb; 20(2):66-71. PubMed ID: 10098324
[TBL] [Abstract][Full Text] [Related]
30. Escape of human immunodeficiency virus from immune control.
McMichael AJ; Phillips RE
Annu Rev Immunol; 1997; 15():271-96. PubMed ID: 9143689
[TBL] [Abstract][Full Text] [Related]
31. HIV-1 Tat protein as a potential AIDS vaccine.
Goldstein G
Nat Med; 1996 Sep; 2(9):960-4. PubMed ID: 8782444
[No Abstract] [Full Text] [Related]
32. CD8+ cells in human immunodeficiency virus type I pathogenesis: cytolytic and noncytolytic inhibition of viral replication.
Yang OO; Walker BD
Adv Immunol; 1997; 66():273-311. PubMed ID: 9328644
[No Abstract] [Full Text] [Related]
33. Molecular insights into human immunodeficiency virus type 1 pathogenesis.
Feinberg MB; Greene WC
Curr Opin Immunol; 1992 Aug; 4(4):466-74. PubMed ID: 1356348
[TBL] [Abstract][Full Text] [Related]
34. MHC-restricted cytotoxicity against HIV.
Autran B; Plata F; Debre P
J Acquir Immune Defic Syndr (1988); 1991; 4(4):361-7. PubMed ID: 1706768
[No Abstract] [Full Text] [Related]
35. Do cytotoxic T lymphocytes clear some HIV/SIV infections?
Ada G
J Med Primatol; 1996 Jun; 25(3):158-62. PubMed ID: 8892036
[TBL] [Abstract][Full Text] [Related]
36. [Mechanism of HIV replication].
Adachi A; Yamamoto Y; Sone S
Uirusu; 1996 Dec; 46(2):145-54. PubMed ID: 9123886
[No Abstract] [Full Text] [Related]
37. Promises and pitfalls in the reconstitution of immunity in patients who have HIV-1 infection.
Gandhi RT; Walker BD
Curr Opin Immunol; 2002 Aug; 14(4):487-94. PubMed ID: 12088684
[TBL] [Abstract][Full Text] [Related]
38. Cytotoxic T lymphocytes and HIV-1 related neurologic disorders.
Kalams SA; Walker BD
Curr Top Microbiol Immunol; 1995; 202():79-88. PubMed ID: 7587372
[TBL] [Abstract][Full Text] [Related]
39. Multiple cytotoxic effector cells are induced by infection with the human immunodeficiency virus.
Rivière Y; Tanneau-Salvadori F; Regnault A; Lopez O; Sansonetti P; Guy B; Kieny MP; Fournel JJ; Montagnier L
Res Immunol; 1989 Jan; 140(1):110-5; discussion 121. PubMed ID: 2657908
[No Abstract] [Full Text] [Related]
40. HIV-1: seven facets of functional molecular mimicry.
Bjork RL
Immunol Lett; 1991 May; 28(2):91-6; discussion 97-9. PubMed ID: 1885213
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
